Dr. Jan Griffin, amyloidosis cardiologist at the Medical University of South Carolina, discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.
Understanding Living with Amyloidosis: Insights from the ARC Annual Community Survey
Sabrina Rebello, ARC's Senior Research Manager, presented an in-depth overview of key insights from our Annual Community Survey. This webinar focused on understanding the experiences of patients and caregivers throughout their diagnostic journey and ongoing care.
Kristen Hsu, ARC’s Executive Director of Research, presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.
Dr. Meghan Beier, psychologist at the Rowan Center for Behavioral Medicine, explored the emotional aspects of amyloidosis. She discussed mental health issues in amyloidosis and present strategies for coping.
Dr. Sarah Cuddy, cardiologist at Brigham and Women's Hospital, explored the basics of amyloidosis. She presented an introduction to amyloidosis, the different types, and the available treatments. The webinar concluded with a Q&A session.
ARC Executive Director of Research Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on ATTR amyloidosis. Kristen will discussed the direction of future research. The webinar concluded with a Q&A session.
To wrap up 2024, this month’s ARC Talks Webinar consisted of a conversation with ARC staff. We shared highlights from 2024, started to look ahead to 2025, and answered your questions about the work we do for the amyloidosis community.
In honor of National Family Caregivers Month, ARC hosted a discussion between Debra Ruehlman, amyloidosis family caregiver, and Ann Payne, MSW, ARC Clinical Care and Education Manager. This webinar explored topics such as self care, self advocacy, and community resources.
Covering information on Medicare basics, choosing a Part D plan, and coverage gaps, ARC was joined by Sylvia Gary from the Centers for Medicare and Medicaid Services (CMS).
ARC's own Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.
The dedicated team behind the transformative initiatives of ARC discuss the impactful work of the Leadership, Research, Development, Communications, and Community Alliance departments.
Knowing Your Rights: Understanding Health insurance Coverage
Alicia Lawrence, Information and Resource Services Manager at the National Organization for Rare Disorders (NORD), discussed health insurance policies within private and government issued insurance.
Dr. Nelson Leung focused on renal involvement in AL, AA, ALECT2 and ATTR amyloidosis, while discussing treatment and response assessments for each type.
Cardiac and Neurological Approaches in ATTR Management
Dr. Nativi-Nicolau and Dr. Elizabeth Mauricio discussed the decision pathway in management of ATTR amyloidosis from the cardiac and neurological standpoint.
Approaches to Treating Relapsed and Refractory AL Amyloidosis
Dr. Heather Landau discussed current treatment options for relapsed and refractory AL amyloidosis patients.
Dr. Landau also talked about the current testing methodology used to monitor a patient’s disease status, and the role maintenance therapy may play in the management of relapsed AL amyloidosis.
The Fundamentals of Clinical Trials and Current Advances in Amyloidosis Research
Dr. Morie Gertz gave a 101 overview of clinical trials, including consideration in how they are designed, and the phases needed for drug development.
Dr. Gertz also discussed current clinical trials that are evaluating the next generation of drugs for the treatment of AL and ATTR amyloidosis.
Hereditary ATTR Amyloidosis: The Role of Genetic Testing and Recommendations for Genetic Carriers
Cardiologist Dr. Ahmad Masri MD, MS and genetic counselor Emily Brown, MGC, CGC discuss the role of genetic testing in hereditary ATTR amyloidosis care, along with providing disease management recommendations for genetic carriers.
The Role of Stem Cell Transplants in AL Amyloidosis Treatment
Sandy Wong, MD, and Nancy Wong, NP, discuss autologous stem cell transplantation as a therapy choice for AL amyloidosis patients.
Dr. Wong outlines each phase of the process and goes over the function of stem cell transplants in the context of medical care. Nancy Wong discusses how to prepare for a stem cell transplant while highlighting key care considerations for each phase of therapy. Her concluding remarks focus on important considerations during the recovery period.
Overview of ARC’s Research Programs and Results of the Patient Community Survey
Kristen Hsu, Executive Director of Research, and Sabrina Rebello, Research Manager, provide an overview of ARC’s research programs, share findings from our 2022 community survey results, and highlight the future direction of ARC’s research.
Briana Pineau, MS, RD, LDN, a registered dietician at Boston Medical Center, discusses the role nutrition can play in the management of amyloidosis symptoms. In addition to covering gastrointestinal involvement associated with various types of amyloidosis, Briana covers the broader health benefits of a balanced diet.
Join our email list to stay up to date on the latest Amyloidosis news.
To wrap up 2024, this month’s ARC Talks Webinar consisted of a conversation with ARC staff. We shared highlights from 2024, started to look ahead to 2025, and answered your questions about the work we do for the amyloidosis community.
The webinar concluded with a Q and A session.
Original Presentation Date:
December 18, 2024
0:00 — Intro
2:01 — Shaping ARC’s Purpose
5:03 — Research Overview
7:28 — The Amyloidosis Forum
9:23 — Healthcare Professional Survey
10:40 — Amyloidosis Community Survey
14:00 — CASE: Community and Stakeholder Engagement Overview
17:09 — Patient Support & Patient Programs
20:05 — Healthcare Provider Programs
23:54 — My Amyloidosis Pathfinder (MAP)
26:44 — ASPIRE: Amyloidosis Stakeholder Partnerships for Impact, Reach and Equity
31:29 — Development & Communications Overview
35:51 — Communications Highlights
38:36 — Development Highlights
40:48 — Q&A Session
41:43 — How do I stay informed about amyloidosis clinical trials?
43:43 — What can do if I’m too well for a clinical trial?
47:03 — What can be done for rarer types of amyloidosis?
50:36 — How does ARC engage with healthcare clinics and treatment centers?
52:48 — How does ARC impact rare diseaes public policy?
54:24 — How can people help ARC and the amyloidosis community?